Effective August 2, 2022, mdxhealth has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences. To help ensure a smooth transition for patients, continue to place orders for this test through the existing Exact Sciences portal until further notice. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the Oncotype DX GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the following press release. Questions? Email: gps@mdxhealth.com

Approximately 20% of all new breast cancers diagnosed in the United States are ductal carcinoma in situ (DCIS),1 and no two DCIS patients—or their tumors—are the same.

A pre-invasive form of breast cancer in which tumor cells are confined within the milk ducts, DCIS is typically non-lethal but treatments—such as surgery, radiation therapy, and hormonal therapy—can cause both short term and long-term side effects.

Exact Sciences’ Oncotype DX Breast DCIS Score® test enables women and their doctors to personalize their treatment decisions and potentially forgo unnecessary treatment, such as radiation, when they have a low score and a low risk of local recurrence. For those with higher scores, the result confirms that they would indeed benefit from a more aggressive local approach to treatment, such as radiation therapy.